Table 2.

Occurrence of fracture according to study group.

	Rosuvastatin (n=8901		Placebo (n=8901)		Hazard ratio	p*
	No. of patients	Incidence rate (per 100 person- years)	No. of patients	Incidence rate (per 100 person-years)
Incident fracture†	221	1.20	210	1.14	1.06(0.88–1.28)	0.53
Men	99	0.85	105	0.89	0.97(0.74–1.28)	0.83
Women	122	1.80	105	1.58	1.16(0.89–1.50)	0.28
Hip	23	0.12	14	0.07	1.67(0.85–3.23)	0.14
Vertebral	22	0.12	18	0.10	1.23(0.66–2.30)	0.52
Upper Extremity	72	0.39	65	0.35	1.12(0.80–1.56)	0.53
Lower Extremity	71	0.38	64	0.34	1.13(0.80–1.58)	0.50
Skull, face, finger, toe	29	0.16	25	0.13	1.17(0.69–2.00)	0.57
Other	25	0.13	35	0.19	0.73(0.43–1.21)	0.22

^*Adjusted for age (continuous), sex, blood pressure ≥140/90 mmHg or use of anti-hypertensive medications (yes/no), current tobacco use (yes/no), body mass index (categories: <25, 25–30, ≥30 kg/m²) exercise (categories: rarely or less than once per week, once/week, 2–6 times/week, daily), race, alcohol use (categories: ≤1–3 times/month, 1–6 times/week, 1–3 times/day, ≥4 times/day), baseline HbA1c in quartiles (<5.5, 5.5–5.7, 5.7–5.9, >5.9%), hs-CRP in tertiles (<3.2, 3.2–5.8, ≥5.8) and previous fracture history.

^†Only the first fracture is included in incident fracture. Some participants had multiple fractures. All confirmed fractures are included in hip, vertebral, upper extremity, lower extremity, skull, face, finger, toe and other categories.